RLTM02 [Anti-PAP 2, DB91 5A3.3.2]細胞
ATCC Number： HB-8523?
生長狀態： 懸浮生長
運輸方式： 凍存運輸
是否是腫瘤細胞： 0
物種來源： 小鼠
數量： 大量
細胞形態： **樣
**類型： IgG1
RLTM02 [Anti-PAP 2, DB91 5A3.3.2]細胞Designations: RLTM02 [Anti-PAP 2, DB91 5A3.3.2]
Depositors: Cetus Corp.
Isotype: IgG1
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology: lymphoblast
Source: RLTM02 [Anti-PAP 2, DB91 5A3.3.2]細胞Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against human prostatic acid phosphatase (PAP)
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Comments: Animals were immunized with purified PAP from human semen.
Spleen cells were fused with Sp2/0-Ag14 myeloma cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell-culture-grade water. To make the complete growth medium, add the following components to the base medium:
RLTM02 [Anti-PAP 2, DB91 5A3.3.2]細胞fetal bovine serum to a final concentration of 10%
1.5 g/L sodium bicarbonate for use with 5% CO2 in air atmosphere.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: recommended serum:ATCC 30-2020
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 46-X
References: 3896: M'Timkulu T, et al. RLTM02 [Anti-PAP 2, DB91 5A3.3.2]細胞Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay. US Patent 4,690,890 dated Sep 1 1987
